Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

April Bowles

Nurse Practitioner, Family South Charleston, WV Nurse Practitioner

NPI 1780180745 CMS profile 11014580

4610 Kanawha Ave Sw Ste 200, South Charleston, WV 25309

Open in the dashboard

General payments

$10,072

123 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, April Bowles of South Charleston, WV is reported in the CMS Open Payments database as having received $10,072 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $554 7
2024 General $2,386 22
2023 General $3,639 37
2022 General $2,966 34
2021 General $526 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • April Bowles
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to April Bowles were reported at $554. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year April Bowles Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $526 $124 $35–$379 $132
2022 $2,966 $141 $44–$430 $149
2023 $3,639 $154 $49–$476 $160
2024 $2,386 $165 $51–$504 $164
2025 $554 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,459 36 payments
  2. Abbott Laboratories $2,831 20 payments
  3. Edwards Lifesciences Corporation $1,911 12 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $533 26 payments
  5. Boston Scientific Corporation $364 7 payments
  6. E.R. Squibb & Sons, L.L.C. $315 12 payments
  7. Recor Medical Inc $252 3 payments
  8. Kestra Medical Technology Services, Inc. $170 3 payments
  9. Esperion Therapeutics, Inc. $125 1 payment
  10. HeartFlow, Inc. $51 1 payment
  11. Other $61 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $5,457 23 payments
  2. Food and Beverage $4,525 99 payments
  3. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. COREVALVE EVOLUT R $3,365 34 payments
  2. MITRACLIP Vascular $1,581 9 payments
  3. MITRACLIP Structural Heart $811 5 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $705 9 payments
  5. LifeVest $533 26 payments
  6. MITRACLIP Vascular $326 5 payments
  7. WATCHMAN Access System $233 3 payments
  8. ELIQUIS $190 11 payments
  9. Assure WCD $156 2 payments
  10. Paradise Ultrasound Renal Denervation System $127 2 payments
  11. Other $996 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

199

Median for Nurse Practitioner: 389

Drug cost

$47,990

Median for Nurse Practitioner: $21,885

Branded share of claims

74.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 36 $33,324
Farxiga Dapagliflozin Propanediol Brand 16 $13,079
Clopidogrel Clopidogrel Bisulfate Brand 96 $1,115
Metoprolol Succinate Generic 18 $305
Spironolactone Generic 20 $151
Prednisone Generic 13 $16

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$11,330

Medicare's payments for the services billed

Medicare patients

160

Average age 78

Services billed

220

81 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 58%
Chronic kidney disease 52%
Diabetes 46%
Arthritis 46%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record